Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB), caught up with Proactive's Andrew Scott as the drug developer gears up for the commercial launch of its next-generation antibiotic.
Motif has successfully concluded a second phase III clinical trial on its lead drug, iclaprim and is preparing for regulatory sign-off in America and Europe.
It's initiated a rolling submission to the US Food and Drug Administration, while it is also preparing a marketing authorisation application to the European Medicines Agency.
Meet Highlands Natural Resources Plc, Wishbone Gold PLC, Eurasia Mining plc, Providence Resources PLC and Galileo Resources PLC at our event,London, 19 April 2018.Register here >>